For over 30 years, Eli Lilly and Company has been a global leader in the fight against Alzheimer’s disease.  

Lilly’s neurodegeneration pipeline is one of the deepest in the industry and is shaped by the discoveries we’ve made over nearly three decades of research and development. Our current program focuses predominantly on developing disease-modifying therapies that slow or halt the progression of Alzheimer’s disease. We’re also studying ways to treat the symptoms of other forms of dementia. Lilly is honoured to be a part of leading independent collaborations in the broader Alzheimer’s disease scientific community.